Canada · Delayed Price · Currency is CAD Gilead Sciences Company Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients.
Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19.
The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies.
The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program.
The company was incorporated in 1987 and is headquartered in Foster City, California.
| Country | United States |
| Founded | 1987 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 17,600 |
| CEO | Daniel P. O'Day |
Contact Details
Address: 333 Lakeside Drive Foster City, California 94404 United States | |
| Phone | 650 574 3000 |
| Website | gilead.com |
Stock Details
| Ticker Symbol | GILD |
| Exchange | Toronto Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Daniel P. O'Day | Chairman and Chief Executive Officer |
| Andrew D. Dickinson | Chief Financial Officer |
| Johanna Mercier | Chief Commercial Officer |
| Erin Burkhart | SVice President, Controller and Principal Accounting Officer |
| Jacquie Ross C.F.A. | Senior Vice President of Treasury and Investor Relations |
| Keeley Wettan | Executive Vice President and General Counsel of Legal and Compliance |
| Jyoti K. Mehra | Executive Vice President of Human Resources |
| Dr. Linda Slanec Higgins Ph.D. | Senior Vice President of Research, Innovation and Portfolio |
| Dr. Flavius Martin M.D. | Executive Vice President of Research |
| Janet Dorling | Senior Vice President of Intercontinental Region and Global Patient Solutions |